Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

AgomAb Therapeutics / Equity Capital Markets

<ul><li>✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality &amp; Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under the ticker AGMB as a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibrotic and inflammatory conditions.</li><li>The IPO consists of approximately 12.5 million American Depositary Shares (ADS) priced between $15-$17 per ADS, with additional capacity through an underwriter overallotment.</li><li>At the midpoint, the offering raises just over $200 million and implies a valuation in the high hundreds of millions.</li></ul>

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality &amp; Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under the ticker AGMB as a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibrotic and inflammatory conditions.The IPO consists of approximately 12.5 million American Depositary Shares (ADS) priced between $15-$17 per ADS, with additional capacity through an underwriter overallotment.At the midpoint, the offering raises just over $200 million and implies a valuation in the high hundreds of millions.

<ul><li>AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO activity selectively reopens in early 2026.</li><li>The company plans to offer 12.5 million ADSs at a proposed price range of $15.00 to $17.00 per share , raising approximately $200 million in gross proceeds at the $16.00 midpoint , before underwriting expenses.</li><li>At the midpoint, AgomAb would have an implied equity value of approximately $780 million , based on roughly 48.7 million shares outstanding following the offering.</li></ul>

AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO activity selectively reopens in early 2026.The company plans to offer 12.5 million ADSs at a proposed price range of $15.00 to $17.00 per share , raising approximately $200 million in gross proceeds at the $16.00 midpoint , before underwriting expenses.At the midpoint, AgomAb would have an implied equity value of approximately $780 million , based on roughly 48.7 million shares outstanding following the offering.

AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Agomab Therapeutics (AGMB US) set IPO terms for a February 6 debut amid a busy issuance week, targeting a $731–$829 million market capitalization.</li>
<li>The company is offering 12.5 million primary ADSs at $15–$17, with proceeds funding fibrosis-focused clinical programs and pipeline expansion.</li>
<li>Backed by blue-chip biotech and crossover investors, Agomab enters public markets well capitalized ahead of key clinical milestones.</li>
</ul>


Agomab Therapeutics (AGMB US) set IPO terms for a February 6 debut amid a busy issuance week, targeting a $731–$829 million market capitalization.
The company is offering 12.5 million primary ADSs at $15–$17, with proceeds funding fibrosis-focused clinical programs and pipeline expansion.
Backed by blue-chip biotech and crossover investors, Agomab enters public markets well capitalized ahead of key clinical milestones.


AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

<ul>
<li>AgomAb Therapeutics (AGMB US) filed for a January 16 IPO, targeting a potential February debut to fund mid-stage clinical development in fibrotic diseases.</li>
<li>Lead asset ontunisertib targets fibrostenosing Crohn’s disease via GI-restricted TGFβ/ALK5 inhibition, addressing a large, underserved patient population with no approved therapies.</li>
<li>Backed by ~$330M from blue-chip investors including Fidelity, Redmile, Pfizer, and Sanofi, the company looks to enter public markets with strong validation and balance sheet strength.</li>
</ul>


AgomAb Therapeutics (AGMB US) filed for a January 16 IPO, targeting a potential February debut to fund mid-stage clinical development in fibrotic diseases.
Lead asset ontunisertib targets fibrostenosing Crohn’s disease via GI-restricted TGFβ/ALK5 inhibition, addressing a large, underserved patient population with no approved therapies.
Backed by ~$330M from blue-chip investors including Fidelity, Redmile, Pfizer, and Sanofi, the company looks to enter public markets with strong validation and balance sheet strength.


AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

Belgium

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications. The company's pipeline includes small molecule and antibody product candidates, such as Ontunisertib (AGMB-129) for Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AgomAb Therapeutics (AGMB US)

IPO Rating: AgomAb Therapeutics NV

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality & Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under...

IPO Prophet

AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline

AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO...

IPO Prophet

AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

Agomab Therapeutics plans IPO debut on Feb 6, aiming for $731-$829 million market cap with 12.5 million ADSs at $15-$17 to fund fibrosis programs...

IPO Boutique

AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

AgomAb Therapeutics files for IPO to fund mid-stage development in fibrotic diseases, targeting underserved patient population with GI-restricted...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

IPO Rating: AgomAb Therapeutics NV

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality & Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under...

IPO Prophet

AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline

AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO...

IPO Prophet

AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

​Agomab Therapeutics plans IPO debut on Feb 6, aiming for $731-$829 million market cap with 12.5 million ADSs at $15-$17 to fund fibrosis programs...

IPO Boutique

AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

​AgomAb Therapeutics files for IPO to fund mid-stage development in fibrotic diseases, targeting underserved patient population with GI-restricted...

IPO Boutique

Agomab Therapeutics plans IPO debut on Feb 6, aiming for $731-$829 million market cap with 12.5 million ADSs at $15-$17 to fund fibrosis programs...

AgomAb Therapeutics files for IPO to fund mid-stage development in fibrotic diseases, targeting underserved patient population with GI-restricted...